BEDFORD, Mass.--(BUSINESS WIRE)--Sep. 3, 2015--
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company
focused on the development and commercialization of innovative therapies
for diseases and conditions of the eye, today announced that Amar
Sawhney, Ph.D., President and Chief Executive Officer, will participate
in two upcoming investor conferences in September including:
-
Citi 10th Annual Biotech Conference
Panel: Envisioning the
Future of Novel Ophthalmic Therapies and Drug Delivery Strategies
Wednesday,
September 9, 2015 at 1:00 p.m. Eastern Time
The Mandarin Oriental
Hotel, New York, NY
-
2015 Morgan Stanley Global Healthcare Conference
Wednesday,
September 16, 2015 at 1:05 p.m. Eastern Time
The Grand Hyatt
Hotel, New York, NY
A live audio webcast of the corporate presentation at the Morgan Stanley
Global Healthcare Conference can be accessed through the Calendar of
Events section of the Company's website at investors.ocutx.com. A Replay
of the webcast will be available on the Company's website for two weeks
following the presentation.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company
focused on the development and commercialization of innovative therapies
for diseases and conditions of the eye using its proprietary hydrogel
platform technology. Ocular Therapeutix's lead product candidates are in
Phase 3 clinical development for post-surgical ocular inflammation and
pain and allergic conjunctivitis, and Phase 2 clinical development for
glaucoma, and inflammatory dry eye disease. The Company is also
evaluating sustained-release injectable anti-VEGF drug depots for
back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure®
Sealant, is FDA-approved to seal corneal incisions following cataract
surgery.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150903006186/en/
Source: Ocular Therapeutix, Inc.
Investors:
Ocular Therapeutix, Inc.
Brad Smith
Chief
Financial Officer
bsmith@ocutx.com
or
Burns
McClellan on behalf of Ocular Therapeutix
Kimberly Minarovich,
212-213-0006
kminarovich@burnsmc.com
or
Media:
Scott
Corning
Vice President of Sales and Marketing
scorning@ocutx.com
